SCHEMBL25243775

SCHEMBL25243775

O=C(NCC1CCCCC1)c1csc(-c2cnn(-c3ccccc3)c2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.52
ACKR3 P25106 1/20 0.47
CNR1 P21554 2/20 0.44
PIN1 Q13526 2/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
CLK2 P49760 2/20 0.42
LRRK2 Q5S007 1/20 0.42
P2RX7 Q99572 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
HDAC6 Q9UBN7 2/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HIF1A Q16665 1/20 0.41
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
CHRNA7 P36544 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25233639 0.91 USP30 (0.51) USP30ACKR3CYP1A2CYP3A4CYP2C9
SCHEMBL25230167 0.87 USP30 (0.49) USP30ACKR3CYP1A2CYP3A4CYP2C9
SCHEMBL25237287 0.87 USP30 (0.49) USP30ACKR3CYP1A2CYP3A4CYP2C9
SCHEMBL25238874 0.87 USP30 (0.49) USP30ACKR3CYP1A2CYP3A4CYP2C9
SCHEMBL25233750 0.85 PIN1 (0.53) ACKR3CNR1PIN1CLK2LRRK2
SCHEMBL25206616 0.83 CYP1A2 (0.49) USP30ACKR3CYP1A2CYP3A4CYP2C9
SCHEMBL25238847 0.82 HPGDS (0.57) USP30ACKR3PIN1CYP1A2CYP3A4
SCHEMBL25245452 0.81 CYP1A2 (0.47) USP30ACKR3CYP1A2CYP3A4CYP2C9
SCHEMBL25510789 0.81 HPGDS (0.49) ACKR3CYP1A2CYP3A4CYP2C9HPGD
SCHEMBL25551810 0.80 HPGDS (0.51) USP30ACKR3CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034127-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS UNIVERSITÉ PARIS CITÉ (FR) 2025-01-30 US claimed
EP-4433162-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS Samsara Therapeutics Inc. (US) 2024-09-25 EP claimed
CN-118647613-A Autophagy inducing compounds and uses thereof, in particular for central nervous system diseases 轮回治疗公司 2024-09-13 CN claimed
WO-2023089052-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS Samsara Therapeutics Inc. (US) 2023-05-25 WO claimed
US-20250034127-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS UNIVERSITÉ PARIS CITÉ (FR) 2025-01-30 US disclosed
EP-4183449-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF Samsara Therapeutics Inc. (US) 2023-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034127-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS SQSTM1, TFEB, BECN1 USP30 1478/4885ACKR3 2126/4885CNR1 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.